MARKET

ELVN

ELVN

Enliven Therapeutics Inc
NASDAQ
50.08
+0.96
+1.95%
After Hours: 49.73 -0.35 -0.70% 18:31 06/26 EDT
OPEN
49.00
PREV CLOSE
49.12
HIGH
50.45
LOW
48.47
VOLUME
6.64M
TURNOVER
--
52 WEEK HIGH
50.56
52 WEEK LOW
14.79
MARKET CAP
3.50B
P/E (TTM)
-30.1088
1D
5D
1M
3M
1Y
5Y
1D
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
The Motley Fool · 1d ago
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
The Motley Fool · 1d ago
22% Below Analyst Target, Is Enliven Therapeutics (ELVN) Fairly Valued Here
Simply Wall St · 2d ago
Major Investor Makes Bold Exit Move in Enliven Therapeutics Stock
TipRanks · 3d ago
OrbiMed Advisors reports Enliven Therapeutics common stock sale worth $38.02 million
PUBT · 4d ago
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?
The Motley Fool · 4d ago
Enliven Therapeutics CMO Helen Louise Collins disposes of USD 217,816 in common shares
PUBT · 6d ago
Enliven Therapeutics: Continuing The Pop Off; What Could Go Wrong?
Seeking Alpha · 6d ago
More
About ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.

Webull offers Enliven Therapeutics Inc stock information, including NASDAQ: ELVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELVN stock methods without spending real money on the virtual paper trading platform.